Xyrem(oxybate)
Lumryz, Xyrem, Xywav (oxybate) is a small molecule pharmaceutical. Oxybate was first approved as Xyrem on 2002-07-17. It is used to treat cataplexy in the USA. It has been approved in Europe to treat cataplexy and narcolepsy.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| nervous system diseases | D009422 |
| mental disorders | D001523 |
Trade Name
FDA
EMA
Lumryz, Oxybate, Xyrem (discontinued: Oxybate)
CombinationsXywav
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Calcium oxybate
+
Magnesium oxybate
+
Potassium oxybate
+
Sodium oxybate
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| XYWAV | Jazz Pharmaceuticals | N-212690 RX | 2020-07-21 | 1 products, RLD, RS |
Sodium oxybate
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| LUMRYZ | Avadel Pharmaceuticals | N-214755 RX | 2023-05-01 | 4 products, RLD |
| XYREM | Jazz Pharmaceuticals | N-021196 RX | 2002-07-17 | 1 products, RLD, RS |
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| lumryz | New Drug Application | 2025-04-10 |
| n/a | NDA authorized generic | 2022-10-04 |
| sodium oxybate | ANDA | 2025-05-19 |
| xyrem | New Drug Application | 2025-07-01 |
| xywav | New Drug Application | 2025-07-01 |
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
SODIUM OXYBATE, LUMRYZ, AVADEL CNS | |||
| 2030-05-01 | ODE-431 | ||
| 2026-05-01 | NP | ||
CALCIUM OXYBATE / MAGNESIUM OXYBATE / POTASSIUM OXYBATE / SODIUM OXYBATE, XYWAV, JAZZ | |||
| 2028-08-12 | ODE-369 | ||
| 2027-07-21 | ODE-361 | ||
| 2024-08-12 | I-870 | ||
| 2023-07-21 | NP | ||
SODIUM OXYBATE, XYREM, JAZZ PHARMS | |||
| 2026-04-26 | PED | ||
| 2025-10-26 | ODE-231 | ||
Patent Expiration
Patent | Expires | Flag | FDA Information |
|---|---|---|---|
| Sodium Oxybate, Lumryz, Avadel Cns | |||
| 11583510 | 2042-02-07 | U-3578 | |
| 10925844 | 2040-02-28 | DP | |
| 10272062 | 2037-07-21 | DP | |
| 10736866 | 2037-07-21 | DP | |
| 10952986 | 2037-07-21 | U-3601 | |
| 10973795 | 2037-07-21 | DP | |
| 11000498 | 2037-07-21 | DP | U-3580 |
| 11052061 | 2037-07-21 | DP | |
| 11065224 | 2037-07-21 | DP | |
| 11400065 | 2037-07-21 | U-3579 | |
| 11504347 | 2037-07-21 | DP | |
| 11602512 | 2037-07-21 | U-3577 | |
| 11602513 | 2037-07-21 | U-3576 | |
| Calcium Oxybate / Magnesium Oxybate / Potassium Oxybate / Sodium Oxybate, Xywav, Jazz | |||
| 11426373 | 2037-09-19 | U-3432 | |
| 8772306 | 2033-03-15 | U-1532, U-3198 | |
| 9050302 | 2033-03-15 | U-1532 | |
| 9486426 | 2033-03-15 | U-1532 | |
| 10213400 | 2033-03-15 | U-2499 | |
| 10864181 | 2033-03-15 | U-1532, U-3017 | |
| 11253494 | 2033-03-15 | U-3323, U-3324 | |
| 8591922 | 2033-01-11 | DP | |
| 8901173 | 2033-01-11 | DP | |
| 9132107 | 2033-01-11 | DP | |
| 10195168 | 2033-01-11 | DP | |
| 10675258 | 2033-01-11 | U-2938 | |
| 11554102 | 2033-01-11 | DP | |
| Sodium Oxybate, Xyrem, Jazz Pharms | |||
| 7668730 | 2024-06-16 | U-1110 | |
ATC Codes
HCPCS
No data
Clinical
Clinical Trials
64 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Narcolepsy | D009290 | EFO_0000614 | G47.4 | — | — | 4 | 3 | 1 | 8 |
| Disorders of excessive somnolence | D006970 | — | G47.1 | — | 1 | 1 | 1 | — | 3 |
| Sleepiness | D000077260 | — | R40.0 | — | 1 | 1 | 1 | — | 3 |
| Parkinson disease | D010300 | EFO_0002508 | G20 | — | 1 | — | 1 | — | 2 |
| Rem sleep behavior disorder | D020187 | EFO_0007462 | G47.52 | — | — | — | 1 | — | 1 |
| Mental disorders | D001523 | EFO_0000677 | F91.9 | — | — | — | 1 | — | 1 |
| Obstructive sleep apnea | D020181 | EFO_0003918 | G47.33 | — | — | — | 1 | — | 1 |
| Sleep apnea syndromes | D012891 | EFO_0003877 | G47.3 | — | — | — | 1 | — | 1 |
| Apnea | D001049 | — | R06.81 | — | — | — | 1 | — | 1 |
| Sleep | D012890 | GO_0030431 | — | — | — | — | 1 | — | 1 |
Show 4 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Myofascial pain syndromes | D009209 | EFO_1001054 | — | — | 1 | 4 | — | — | 5 |
| Fibromyalgia | D005356 | EFO_0005687 | M79.1 | — | 1 | 4 | — | — | 5 |
| Cataplexy | D002385 | — | — | — | — | 1 | — | — | 1 |
| Bulimia | D002032 | — | F50.2 | — | 1 | 1 | — | — | 1 |
| Feeding and eating disorders | D001068 | — | F50 | — | 1 | 1 | — | — | 1 |
| Binge-eating disorder | D056912 | — | F50.2 | — | 1 | 1 | — | — | 1 |
| Pain | D010146 | EFO_0003843 | R52 | — | — | 1 | — | — | 1 |
| Arthralgia | D018771 | — | M25.5 | — | — | 1 | — | — | 1 |
| Myalgia | D063806 | — | M79.1 | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hemiplegia | D006429 | — | G81.0 | 1 | 1 | — | — | — | 1 |
| Sleep initiation and maintenance disorders | D007319 | — | F51.01 | — | 1 | — | — | — | 1 |
| Schizophrenia | D012559 | EFO_0000692 | F20 | — | 1 | — | — | — | 1 |
| Dyssomnias | D020920 | — | — | — | 1 | — | — | — | 1 |
| Parasomnias | D020447 | — | G47.5 | — | 1 | — | — | — | 1 |
| Essential tremor | D020329 | EFO_0003108 | G25.0 | — | 1 | — | — | — | 1 |
| Tremor | D014202 | — | R25.1 | — | 1 | — | — | — | 1 |
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Oxybate |
| INN | — |
| Description | 4-hydroxybutyric acid is a 4-hydroxy monocarboxylic acid that is butyric acid in which one of the hydrogens at position 4 is replaced by a hydroxy group. It has a role as a general anaesthetic, a GHB receptor agonist, a sedative and a neurotoxin. It is a 4-hydroxy monocarboxylic acid and a hydroxybutyric acid. It is functionally related to a butyric acid. It is a conjugate base of a 4-hydroxybutyrate. |
| Classification | Small molecule |
| Drug class | GABA analogue, GHB receptor agonists—GABA receptor agonist; Psycholeptic; Depressant; HypnoticSedative |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | O=C(O)CCCO |
Identifiers
| PDB | — |
| CAS-ID | 591-81-1 |
| RxCUI | 1546380 |
| ChEMBL ID | CHEMBL1342 |
| ChEBI ID | 30830 |
| PubChem CID | 10413 |
| DrugBank | DB01440 |
| UNII ID | — |
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
Oxybate – Jazz Pharmaceuticals
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Xyrem – Jazz Pharmaceuticals
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Xywav – Jazz Pharmaceuticals
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 3,736 documents
View more details
Safety
Black-box Warning
Black-box warning for: Lumryz, N/a, Sodium oxybate, Xyrem, Xywav
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
72,990 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use